Dr. Shahin Rafii

Endothelial cells—the cells that line blood vessels—grown alongside leukemia cells become corrupted and rescue the cancer cells from many chemotherapy drugs, a study by Weill Cornell Medicine investigators found.

Two genes working in concert sustain the integrity of healthy blood vessels, Weill Cornell Medicine investigators discovered in new research. 

With a generous gift of $10 million from Board of Fellows member Alan Hartman and his wife, Kim, Weill Cornell Medicine will establish a multidisciplinary research institute to advance organ regeneration and repair.

Three distinguished Weill Cornell Medicine physician-scientists, Dr. Joseph J. Fins, Dr. Rainu Kaushal and Dr. Shahin Rafii, have been elected to the esteemed Association of American Physicians (AAP).

Researchers at Weill Cornell Medicine have identified a key protein that induces the program to build specialized liver blood vessels. The discovery could lead to engineered replacement hepatic tissue to treat common liver diseases.

A protein that masterminds the way DNA is wrapped within chromosomes has a major role in the healthy functioning of blood stem cells, which produce all blood cells in the body, according to a new study from researchers at Weill Cornell Medicine.

Weill Cornell Medicine researchers have received a two-year $500,000 grant from JDRF to evaluate an innovative approach to islet cell transplantation, an experimental treatment for difficult-to-control type 1 diabetes. The research will be conducted in mouse models of this disease.  

A cellular protein whose normal function appears to suppress bone formation may be a potential new target for treating osteoporosis, suggests a collaborative study led by Weill Cornell Medicine and NewYork-Presbyterian investigators.

The specialized endothelial cells that line the blood vessels in the lung may hold the key to treating the common and often-fatal lung disease emphysema, according to a study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.

Dr. Shahin Rafii, director of the Ansary Stem Cell Institute and chief of the Division of Regenerative Medicine at Weill Cornell Medicine, has received an Outstanding Investigator Award (R35) from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH), for an ambitious project to accelerate regenerative medicine technology.

A team led by Weill Cornell Medicine scientists has pioneered a method for manufacturing functioning human blood vessels and demonstrated that they can carry blood in lab-grown model organs and tumors.

Molecules that coordinate the development of highly specialized blood vessels in the kidney have been identified by investigators at Weill Cornell Medicine, University of Texas Southwestern Medical Center and Hofstra University. The findings pave the way toward new strategies for repairing damaged organs.

Eight Weill Cornell Medicine faculty members have been selected for the fifth round of the Daedalus Fund for Innovation awards, a pioneering institutional program that helps advance promising applied and translational research projects and emerging technologies that have commercial potential.

A new therapy that uses blood-vessel-lining cells to regenerate damaged tissue has the potential to treat liver cirrhosis, Weill Cornell Medicine scientists demonstrate in new research.

Researchers at Weill Cornell Medicine have discovered an innovative method to make an unlimited supply of healthy blood cells from the readily available cells that line blood vessels. 

A gene essential for making blood vessels in embryos can successfully transform amniotic cells into therapeutic blood vessel cells.

The tumor microenvironment can determine whether cancer cells become aggressive cancer stem cells that are resistant to treatment and cause cancers to come back after therapy.